Recital 13, Regulation (EU) 2024/2063

In forcesince 30 Jul 2024

The Authority noted in its opinion that a claim on monacolin K from red yeast rice and the maintenance of normal blood LDL-cholesterol concentrations had already been assessed with a favourable outcome by the EFSA Panel on Dietetic Products Nutrition and Allergies (NDA), in 2011 [EFSA Journal 2011;9(7):2304.]. The conditions of use for the claim subject to that opinion also provided for a daily intake of 10 mg monacolin K from any red yeast rice preparation (which would include SYLVAN BIO red yeast rice) in order to obtain the claimed effect.